New antibody injection enters early human trials for lung cancer

NCT ID NCT06612840

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called GNC-077, a multi-specific antibody, in 20 people with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Participants receive the drug by IV every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GNC-077 multi-specific antibody injection
What this could lead to: If successful, this could point toward a new treatment option for advanced lung cancer and other solid tumors.
What could go wrong: This is an early Phase 1 trial with only 20 participants, focused on safety and dosing. It is too soon to know if the drug will be effective or have manageable side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.